OncoChip was developed and validated by Signature Genomics Laboratories in accordance with CLIA ’88 regulations.

OncoChip comes with two distinct microarray options – Copy Number Evaluation (CNE) and Translocation Assessment (TA).

CNE detects all clinically relevant copy-number gains and losses commonly seen by karyotype.

It also measures gains and losses below the resolution of karyotyping and fluorescent in situ hybridization (FISH), providing more detailed information.

The TA microarray option detects the clinically relevant balanced translocations identified by FISH and karyotype and precisely recognizes balanced translocation breakpoints, as well as balanced translocation partners not distinguishable by these methods.

TA also distinguishes between the variable translocation breakpoints within a single gene, which can have a dramatic impact on a patient’s prognosis and treatment.

Clinicians can select from a broad menu of cancer-specific panels that will be run by PerkinElmer‘s Signature Genomics Laboratories, using software applications that have been designed to allow for customization suiting the needs of each individual patient.

The results of the OncoChip microarray technology may allow for treatments of patients with hematological cancers, such as chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myeloid leukemia, T-cell and B-cell acute lymphoblastic leukemia.